Printer Friendly

ICN BIOMEDICALS LAUNCHES NEW, NON-ISOTOPIC TEST KITS

 COSTA MESA, Calif., May 5 /PRNewswire/ -- ICN Biomedicals Inc. (AMEX: BIM), one of the world's leading suppliers of biotechnology research products and medical diagnostics, said today it has received authorization from the U.S. Food and Drug Administration to market non-isotopic test kits for use by laboratories to detect thyroid deficiencies and to determine hormonal levels in women and men.
 Conversion of the test kits from radio-immuno-assay to non- isotopic tests is part of the company's strategy to move toward more technologically advanced products in the diagnostic marketplace.
 The thyroid tests allow doctors to determine how that gland is functioning. The hormonal tests allow physicians to determine potential fertility problems.
 The test kits are based on non-isotopic enzyme techniques.
 ICN Biomedicals has more than 55,000 products and sales in 130 nations. It is a subsidiary of ICN Pharmaceuticals Inc.
 -0- 5/5/93
 /CONTACT: Paul Knopick of ICN Biomedicals, 714-545-0100, ext. 2465/
 (BIM)


CO: ICN Biomedicals; ICN Pharmaceuticals Inc. ST: California IN: MTC SU: PDT

MS-BP -- LA005 -- 4724 05/05/93 09:02 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 5, 1993
Words:175
Previous Article:KENFIL ANNOUNCES THIRD QUARTER RESULTS
Next Article:GUARDIAN BANCORP NAMES BANKING UNIT PRESIDENT AND CHIEF EXECUTIVE OFFICER AND RELEASES FIRST QUARTER 1993 RESULTS
Topics:


Related Articles
ICN AND SUBSIDIARY COMPANIES ANNOUNCE MANAGEMENT APPOINTMENTS
ICN PHARMACEUTICALS ANNOUNCES YEAR-END RESULTS
ICN PHARMACEUTICALS REPORTS PROFIT IN THE FIRST QUARTER; DECONSOLIDATES SPI
ICN BIOMEDICALS ISSUES $62 MILLION IN PREFERRED STOCK
ICN PHARMACEUTICALS REPORTS CONSOLIDATED THIRD QUARTER RESULTS; ALL THREE UNITS POST PROFITS
COMMON STOCKS OF ICN PHARMACEUTICALS, THREE OPERATING UNITS, TOP MAJOR STOCK MARKET INDICES IN 1993
ICN BIOMEDICALS REPORTS THIRD CONSECUTIVE QUARTER OF PROFITABILITY; DEBT SIGNIFICANTLY REDUCED
ICN PHARMACEUTICALS ISSUES STATEMENT ON RECENT MARKET ACTIVITY
ICN PHARMACEUTICALS REPORTS CONSOLIDATED FIRST QUARTER 1994 RESULTS
ICN Biomedicals Launches New Cardiovascular Risk Test.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters